Paul Tudor Jones's VRTX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 51,374 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $20.12 M, representing 0.03% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 46 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in VRTX, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 41,911 shares. Largest reduction occurred in Q1 2021, reducing 29,041 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2014 | +2,178 | New Buy | 2,178 | $94.58 |
| Q3 2014 | +5,548 | Add 254.73% | 7,726 | $112.35 |
| Q4 2014 | -1,137 | Reduce 14.72% | 6,589 | $118.83 |
| Q1 2015 | -6,589 | Sold Out | 6,589 | $0.00 |
| Q2 2015 | +2,729 | New Buy | 2,729 | $123.49 |
| Q3 2015 | -2,729 | Sold Out | 2,729 | $0.00 |
| Q4 2015 | +6,286 | New Buy | 6,286 | $125.84 |
| Q1 2016 | -6,286 | Sold Out | 6,286 | $0.00 |
| Q4 2016 | +9,611 | New Buy | 9,611 | $73.67 |
| Q1 2017 | -9,611 | Sold Out | 9,611 | $0.00 |
| Q4 2017 | +10,416 | New Buy | 10,416 | $149.87 |
| Q1 2018 | -7,985 | Reduce 76.66% | 2,431 | $162.90 |
| Q2 2018 | +15,157 | Add 623.49% | 17,588 | $169.95 |
| Q3 2018 | -9,286 | Reduce 52.80% | 8,302 | $192.72 |
| Q4 2018 | -1,943 | Reduce 23.40% | 6,359 | $165.75 |
| Q1 2019 | -6,359 | Sold Out | 6,359 | $0.00 |
| Q4 2019 | +15,648 | New Buy | 15,648 | $218.94 |
| Q1 2020 | -5,276 | Reduce 33.72% | 10,372 | $237.95 |
| Q2 2020 | -2,585 | Reduce 24.92% | 7,787 | $290.36 |
| Q3 2020 | -2,084 | Reduce 26.76% | 5,703 | $272.14 |
| Q4 2020 | +40,600 | Add 711.91% | 46,303 | $236.33 |
| Q1 2021 | -29,041 | Reduce 62.72% | 17,262 | $214.87 |
| Q2 2021 | -17,262 | Sold Out | 17,262 | $0.00 |
| Q3 2021 | +29,658 | New Buy | 29,658 | $181.40 |
| Q4 2021 | -29,658 | Sold Out | 29,658 | $0.00 |
| Q4 2022 | +7,580 | New Buy | 7,580 | $0.29 |
| Q1 2023 | -7,580 | Sold Out | 7,580 | $0.00 |
| Q3 2023 | +33,355 | New Buy | 33,355 | $347.74 |
| Q4 2023 | -6,950 | Reduce 20.84% | 26,405 | $406.89 |
| Q1 2024 | -2,876 | Reduce 10.89% | 23,529 | $418.01 |
| Q2 2024 | -23,529 | Sold Out | 23,529 | $0.00 |
| Q4 2024 | +9,463 | New Buy | 9,463 | $402.70 |
| Q1 2025 | -9,463 | Sold Out | 9,463 | $0.00 |
| Q3 2025 | +51,374 | New Buy | 51,374 | $391.64 |
Paul Tudor Jones's Vertex Pharmaceuticals Incorporated Investment FAQs
Paul Tudor Jones first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q2 2014, acquiring 2,178 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Vertex Pharmaceuticals Incorporated (VRTX) for 46 quarters since Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q3 2025, adding 51,374 shares worth $20.12 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 51,374 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $20.12 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.03% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 51,374 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.